Trial · NCT03174236

First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition

NCT03174236, Phase 3, Unknown, University of Oxford

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition. Trials, record NCT03174236. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03174236

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition
NCT number: NCT03174236
Status: Unknown
Phases: Phase 3
Enrollment: 2,000 participants, estimated
Lead sponsor: University of Oxford
Conditions: Malnutrition Severe, Antibiotic Resistance, Antibiotic Toxicity
Interventions: Ceftriaxone, Benzyl penicillin, Metronidazole, Placebo, Gentamicin
First posted: 2017-06-02
Last updated: 2020-05-19

Source ClinicalTrials.gov

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mortality	90 days after enrolment.	Mortality is measured using source documents from medical records, verbal autopsy, or death or burial certificates in the community.
Secondary	Mortality during the first 7 days	7 days	Mortality during the first 7 days
Secondary	Mortality during the first 30 days	7 days	Mortality during the first 30 days
Secondary	Index admission inpatient mortality	Through index hospital admission, an average of 7 days.	Mortality during the index hospitalisation, measured using inpatient records.
Secondary	Mortality after discharge from index admission.	90 days after enrolment	Mortality occurring after discharge from the index hospital admission is measured using inpatient medical records, verbal autopsy, or death or burial certificates in the community.
Secondary	Grade 4 toxicity	Up to 7 days following enrolment	Grade 4 toxicity events are measured according to the Division of AIDS Tables for Grading the Severity of Adverse Events using medical records.
Secondary	Serious adverse events	90 days after enrolment.	Serious adverse events are measured using inpatient and outpatient medical records.
Secondary	Tolerability - relevant side effects during the first 7 day	7 days	Vomiting, diarrhoea, NG tube in place and convulsions during the first 7 days
Secondary	Causes of death.	90 days after enrolment	Causes of death, as determined by an endpoint review committee.
Secondary	Re-admission to hospital.	From discharge from hospital to 90 days after enrolment	Re-admission to hospital defined as at least one overnight stay in a hospital or health facility are measured using inpatient records.

1 to 10 of 14Source ClinicalTrials.gov

See all 14 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers25

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
795448	BACKGROUND	PubMed
4940475	BACKGROUND	PubMed
8458315	BACKGROUND	PubMed
15127367	BACKGROUND	PubMed
15635111	BACKGROUND	PubMed
17132297	BACKGROUND	PubMed
17519011	BACKGROUND	PubMed
18318945	BACKGROUND	PubMed
18406865	BACKGROUND	PubMed
19058824	BACKGROUND	PubMed

1 to 10 of 25

See all 25 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03174236

GET https://conductscience.org/api/trials/v1/NCT03174236/papers?page=2

API reference For AI assistants